Multilevel Omics for the Discovery of Biomarkers and Therapeutic Targets for Stroke - PubMed

Multilevel Omics for the Discovery of Biomarkers and Therapeutic Targets for Stroke - PubMed

Multilevel Omics for the Discovery of Biomarkers and Therapeutic Targets for Stroke

Joan Montaner 1 2 3, Laura Ramiro 4, Alba Simats 4, Steffen Tiedt 5, Konstantinos Makris 6, Glen C Jickling 7, Stephanie Debette 8 9, Jean-Charles Sanchez 10, Alejandro Bustamante 4

Affiliations 

• PMID: 32322099
 
• DOI: 10.1038/s41582-020-0350-6

Abstract

Despite many years of research, no biomarkers for stroke are available to use in clinical practice. Progress in high-throughput technologies has provided new opportunities to understand the pathophysiology of this complex disease, and these studies have generated large amounts of data and information at different molecular levels. The integration of these multi-omics data means that thousands of proteins (proteomics), genes (genomics), RNAs (transcriptomics) and metabolites (metabolomics) can be studied simultaneously, revealing interaction networks between the molecular levels. Integrated analysis of multi-omics data will provide useful insight into stroke pathogenesis, identification of therapeutic targets and biomarker discovery. In this Review, we detail current knowledge on the pathology of stroke and the current status of biomarker research in stroke. We summarize how proteomics, metabolomics, transcriptomics and genomics are all contributing to the identification of new candidate biomarkers that could be developed and used in clinical stroke management.

Similar articles

• Translational Metabolomics of Head Injury: Exploring Dysfunctional Cerebral Metabolism with Ex Vivo NMR Spectroscopy-Based Metabolite Quantification.

  Wolahan SM, Hirt D, Glenn TC.In: Kobeissy FH, editor. Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Boca Raton (FL): CRC Press/Taylor & Francis; 2015. Chapter 25.PMID: 26269925 Free Books & Documents. Review.
• Alzheimer's disease in the omics era.

  Sancesario GM, Bernardini S.Clin Biochem. 2018 Sep;59:9-16. doi: 10.1016/j.clinbiochem.2018.06.011. Epub 2018 Jun 18.PMID: 29920246 Review.
• Omics-based biomarkers: current status and potential use in the clinic.

  Quezada H, Guzmán-Ortiz AL, Díaz-Sánchez H, Valle-Rios R, Aguirre-Hernández J.Bol Med Hosp Infant Mex. 2017 May-Jun;74(3):219-226. doi: 10.1016/j.bmhimx.2017.03.003. Epub 2017 May 10.PMID: 29382490 Review.
• Omics Biomarkers in Ophthalmology.

  Lauwen S, de Jong EK, Lefeber DJ, den Hollander Al.Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO88-BIO98. doi: 10.1167/iovs.17-21809.PMID: 28525563 Review.
• Application of OMICS technologies in occupational and environmental health research; current status and projections.

  Vlaanderen J, Moore LE, Smith MT, Lan Q, Zhang L, Skibola CF, Rothman N, Vermeulen R.Occup Environ Med. 2010 Feb;67(2):136-43. doi: 10.1136/oem.2008.042788. Epub 2009 Nov 20.PMID: 19933307 Free PMC article. Review.